Who are Direct renin inhibitor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tekturna, Capozide 25/15, Renin-Angiotensin (RAAS) alone, Early sequential nephron blockade, Aliskiren, Perindopril, Valsartan/aliskiren.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/direct-renin-inhibitor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Direct renin inhibitor — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Direct renin inhibitor (Direct renin inhibitor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct renin inhibitor. Area: Cardiovascular.

phase 2 Direct renin inhibitor Renin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Direct renin inhibitor (Direct renin inhibitor) — Medical Practice Prof D. Ivanov. A direct renin inhibitor blocks the enzyme renin, preventing the initial step of the renin-angiotensin-aldosterone system (RAAS) and reducing blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Direct renin inhibitor TARGET	Direct renin inhibitor	Medical Practice Prof D. Ivanov	phase 2	Direct renin inhibitor	Renin
Tekturna	ALISKIREN	Lxo Ireland	marketed	Renin Inhibitor	Renin	2007-01-01
Capozide 25/15	CAPTOPRIL	Aarxion Anda Hlding	marketed	Thiazide Diuretic [EPC]	Renin	1981-01-01
Renin-Angiotensin (RAAS) alone	Renin-Angiotensin (RAAS) alone	James A. Tumlin, MD	marketed	RAAS inhibitor (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist)	Renin-angiotensin-aldosterone system components (ACE, AT1 receptor, renin, or aldosterone receptor)
Early sequential nephron blockade	Early sequential nephron blockade	University of Parma	marketed	RAAS inhibitor combination strategy	Renin-angiotensin-aldosterone system (multiple targets)
Aliskiren, Perindopril	Aliskiren, Perindopril	Medical University of Gdansk	marketed	Antihypertensive combination (direct renin inhibitor + ACE inhibitor)	Renin and Angiotensin-Converting Enzyme (ACE)
Valsartan/aliskiren	Valsartan/aliskiren	Novartis	marketed	Angiotensin II receptor blocker + direct renin inhibitor combination	AT1 receptor (valsartan); renin (aliskiren)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct renin inhibitor class)

Medical Practice Prof D. Ivanov · 1 drug in this class
Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Direct renin inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/direct-renin-inhibitor. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab